Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Adjuvant Breast Cancer Treatment Condition: Option 1 (Day 1 dose schedule) |
Dose: Intravenous – Epirubicin 100 mg/m², 5-fluorouracil 500 mg/m², and cyclophosphamide 500 mg/m² Frequency: Day 1 Duration: Repeat every 21 days for 6 cycles |
|
Indication: Adjuvant Breast Cancer Treatment Condition: Option 2 (Divided dose schedule) |
Dose: Intravenous and Oral – Epirubicin 60 mg/m² intravenous, 5-fluorouracil 500 mg/m² intravenous, and cyclophosphamide 75 mg/m² oral Frequency: Epirubicin and 5-fluorouracil divided equally between days 1 and 8; cyclophosphamide on days 1-14 Duration: Repeat every 28 days for 6 cycles |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment Serum Creatinine greater than 5 mg/dL [greater than 442 micromoles/L] |
Dose: Not specified – Decrease dose by 50% Note: Test cardiac ejection fraction via multigated acquisition before starting treatment |
Administration
- Give over 3-5 minutes
- Must be diluted properly
Side Effect
- Alopecia (96%)
- Nausea and vomiting (92%)
- Leukopenia or neutropenia (80%)
- Amenorrhea (72%)
- Anemia (72%)
- Mucositis (59%)
- Thrombocytopenia (49%)
- Lethargy (46%)
- Hot flashes (39%)
- Diarrhea (25%)
- Conjunctivitis (15%)
- Rash (9%)
- Fever (5%)
- Skin changes (5%)
- Anorexia (3%)
- Acute lymphoid leukemia
- Acute myelogenous leukemia
- Atrioventricular block
- Esophagitis
- Hyperpigmentation
- Myelodysplastic syndrome
- Myocardial toxicity (including CHF)
- Severe myelosuppression
- Risk of secondary AML
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Paclitaxel, other anthracyclines, cimetidine, heparin, antineoplastic drugs, cardiotoxic drugs, radiation, hepatoactive drugs
|
Interactions noted, but effects not specified
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Cardiac Impairment
|
Risk of heart failure
|
|
Severe Recent MI
|
Risk of cardiac complications
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.